Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis Chesler

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Nature Communications|March 21, 2018
Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and XenopusSandra G Gonzalez Malagon, Anna M Lopez Muñoz, Daniel Doro, et al.
Cancer Cell|May 26, 2012
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYCFredrik J Swartling, Vasil Savov, Anders I Persson, et al.
Nature Genetics|September 4, 2020
Subclonal reconstruction of tumors by using machine learning and population geneticsGiulio Caravagna, Timon Heide, Marc J Williams, et al.
Cancer Letters|September 23, 2024
Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathwaysJodie Bojko, Madhu Kollareddy, Marianna Szemes, et al.
Molecular Cancer Therapeutics|June 24, 2026
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory NeuroblastomaEvon Poon, Tong Liang, Qiong Gao, et al.
Cancer Research|October 3, 2007
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastomaLouis Chesler, David D Goldenberg, Isha T Seales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trialSteven G DuBois, Louis Chesler, Susan Groshen, et al.
Oncotarget|June 25, 2020
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastomaDavid King, Xiao Dun Li, Gilberto S Almeida, et al.
Oncotarget|September 18, 2014
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastomaNathan F Moore, Anna M Azarova, Namrata Bhatnagar, et al.
Open Biology|December 1, 2021
MYC regulates metabolism through vesicular transfer of glycolytic kinasesAlexia Tsakaneli, Victor Corasolla Carregari, Martina Morini, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Nature Communications|March 21, 2018
Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and XenopusSandra G Gonzalez Malagon, Anna M Lopez Muñoz, Daniel Doro, et al.
Cancer Cell|May 26, 2012
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYCFredrik J Swartling, Vasil Savov, Anders I Persson, et al.
Nature Genetics|September 4, 2020
Subclonal reconstruction of tumors by using machine learning and population geneticsGiulio Caravagna, Timon Heide, Marc J Williams, et al.
Cancer Letters|September 23, 2024
Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathwaysJodie Bojko, Madhu Kollareddy, Marianna Szemes, et al.
Molecular Cancer Therapeutics|June 24, 2026
Anti-Tumor Activity of Cdk2/9 Inhibitor Fadraciclib in an In Vivo Model of Temozolomide Refractory NeuroblastomaEvon Poon, Tong Liang, Qiong Gao, et al.
Cancer Research|October 3, 2007
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastomaLouis Chesler, David D Goldenberg, Isha T Seales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trialSteven G DuBois, Louis Chesler, Susan Groshen, et al.
Oncotarget|June 25, 2020
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastomaDavid King, Xiao Dun Li, Gilberto S Almeida, et al.
Oncotarget|September 18, 2014
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastomaNathan F Moore, Anna M Azarova, Namrata Bhatnagar, et al.
Open Biology|December 1, 2021
MYC regulates metabolism through vesicular transfer of glycolytic kinasesAlexia Tsakaneli, Victor Corasolla Carregari, Martina Morini, et al.
Pageof 12